Table 5.

Impact of HPV vaccine in decreasing prevalence and incidence of HPV infection and cervical cancer.

Outcome	Dose of Vaccine	Population Group	Duration after Vaccination	Result
Prevalence of infections of HPV types 6, 11, 16, and 18 [52,65,72]	At least one dose	14–19 years old	4 years	Decreased 56%
			8 years	Decreased 71%
			12 years	Decreased 88%
Prevalence of HPV 6/11/16/18/31/33/45/52/58 infections [65]	At least one dose	14–19 years old	12 years	Decreased 65%
Incidence of cervical squamous cell carcinoma (SCC) [73]	At least one dose	15–20 years old	18 years	Decreased on average by 12.7% per year
		25–29 years old	18 years	Decreased on average by 2.3% per year
Incidence of adenocarcinoma [73]	At least one dose	15–20 years old	18 years	Decreased on average by 4.1 per year
		25–59 years old	18 years	Decreased on average by 1.6 per year
Vaccine efficacy against persistent HPV 16 and 18 infections [74]	Single dose	10–18 years old	9 years	Vaccine efficacy 95.4% (95% CI = 85.0% to 99.9%)
	Two doses	10–18 years old	9 years	Vaccine efficacy 93.1% (95% CI = 77.3% to 99.8%)
	Three doses	10–18 years old	9 years	Vaccine efficacy 93.3% (95% CI = 77.5% to 99.7%)